LALPATHLAB · Healthcare · Diagnostics & Research
Composite scorecard: 61/100 — Quality 92 · Valuation 34 · Growth 47 · Momentum 58
| Share price | ₹1,693.30 |
| Market cap | ₹23,375 Cr |
| P/E ratio | 44.2 |
| P/B ratio | 9.8 |
| ROE | 20.3% |
| ROCE | 28.0% |
| Dividend yield | 0.93% |
| Book value | ₹143.09 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹2,763 Cr | ₹510 Cr | 28.0% |
| 2025 | ₹2,461 Cr | ₹492 Cr | 28.0% |
| 2024 | ₹2,227 Cr | ₹362 Cr | 27.0% |
| 2023 | ₹2,017 Cr | ₹241 Cr | 24.0% |
| 2022 | ₹2,087 Cr | ₹350 Cr | 27.0% |
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.